Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Insulin Resistance × Canagliflozin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 2 Breast Neoplasms 2 Pancreatic Neoplasms 1 Non-alcoholic Fatty Liver Disease 1 Lung Neoplasms 1 Insulin Resistance 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1

Interventions

Metformin 28 Pioglitazone 7 Exercise 7 Inositol 5 Acupuncture Therapy 4 Insulin 3 Ethinyl Estradiol 3 salicylsalicylic acid 2 drospirenone and ethinyl estradiol combination 2 Water 2 Tablets 2 Sugars 2 Resistance Training 2 Preoperative Exercise 2 High-Intensity Interval Training 2 Folic Acid 2 Diet Therapy 2 Cyproterone Acetate 2 Caloric Restriction 2 Biguanides 2 ziprasidone 1 maltodextrin 1 lime 1 licogliflozin 1 drospirenone 1 cinnulin PF 1 adrenosterone 1 Zoledronic Acid 1 World Health Organization oral rehydration solution 1 Vitamin D 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04700839 2022-09-10

PCOS

Shanghai 10th People's Hospital

Phase 4 Completed

Insulin Resistance, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡